checklist original data file s1 targetmol anti cancer compound library Search Results


eed  (Santa Cruz Biotechnology)
91
Santa Cruz Biotechnology eed
Eed, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/Candida+albicans+Antibody/pm38031139-172-14-15
Average 91 stars, based on 1 article reviews
eed - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
normal mouse igg  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology normal mouse igg
Normal Mouse Igg, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/normal+mouse+IgG/pm38031139-172-19-22
Average 96 stars, based on 1 article reviews
normal mouse igg - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
ezh2  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc ezh2
Fig. 3 TRIP12 modulates <t>EZH2</t> target gene expression. A, B Relative mRNA expression of canonically-repressed and noncanonically-activated target genes of EZH2 upon siRNA-mediated knockdown of TRIP12 in YT (A) and NKYS (B). C, D Relative mRNA expression of canonically-repressed and noncanonically-activated target genes of EZH2 upon TRIP12 or empty vector transfection in YT (C) and NKYS (D). Results are mean ± SD. N = 3; N.S. not significant; *p < 0.05; **p < 0.01; ***p < 0.001
Ezh2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/Ezh2+Mouse+mAb/pm38031139-172-34-35
Average 95 stars, based on 1 article reviews
ezh2 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
suz12  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology suz12
Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and <t>SUZ12</t> with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown
Suz12, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/SUZ12+Antibody/pm38031139-172-9-10
Average 94 stars, based on 1 article reviews
suz12 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
ha probe  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology ha probe
Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and <t>SUZ12</t> with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown
Ha Probe, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/HA-Tag+Antibody/pm38031139-172-85-86
Average 96 stars, based on 1 article reviews
ha probe - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
uhrf1  (Santa Cruz Biotechnology)
94
Santa Cruz Biotechnology uhrf1
E3 ligase TRIP12 correlates with EZH2 expression in extranodal natural killer/T-cell lymphoma (ENKTL). A Gene expression profiling (GEP) data showing EZH2 expression in ENKTL: 35 patient samples and 6 normal control tissues. B Co-IP showing interaction between EZH2 and TRIP12 or <t>UHRF1</t> in YT (left) and NK92 cells (right). C EZH2 protein level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. N = 3 individual experiments and representative images are shown. ENKTL cells were harvested for immunoblots 48 h after knockdown with Neon transfection system. D EZH2 mRNA level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. ENKTL cells were harvested for RNA extraction 24 h after knock down. E EZH2 mRNA level change upon Flag-TRIP12 or empty vector transfection in YT (upper) and NKYS (lower) cells. The cells were harvested for RNA extraction 16 h after overexpression. Results are mean ± SD. N = 3; N.S. not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. F linear correlation between TRIP12 and EZH2 expression obtained from GEP data of 35 ENKTL patient samples (R = 0.76, p = 6.9e−07)
Uhrf1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/UHRF1+Antibody/pmc10685657-212-67-68
Average 94 stars, based on 1 article reviews
uhrf1 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
gapdh  (Santa Cruz Biotechnology)
97
Santa Cruz Biotechnology gapdh
E3 ligase TRIP12 correlates with EZH2 expression in extranodal natural killer/T-cell lymphoma (ENKTL). A Gene expression profiling (GEP) data showing EZH2 expression in ENKTL: 35 patient samples and 6 normal control tissues. B Co-IP showing interaction between EZH2 and TRIP12 or <t>UHRF1</t> in YT (left) and NK92 cells (right). C EZH2 protein level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. N = 3 individual experiments and representative images are shown. ENKTL cells were harvested for immunoblots 48 h after knockdown with Neon transfection system. D EZH2 mRNA level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. ENKTL cells were harvested for RNA extraction 24 h after knock down. E EZH2 mRNA level change upon Flag-TRIP12 or empty vector transfection in YT (upper) and NKYS (lower) cells. The cells were harvested for RNA extraction 16 h after overexpression. Results are mean ± SD. N = 3; N.S. not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. F linear correlation between TRIP12 and EZH2 expression obtained from GEP data of 35 ENKTL patient samples (R = 0.76, p = 6.9e−07)
Gapdh, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/GAPDH+Antibody/pm38031139-172-47-48
Average 97 stars, based on 1 article reviews
gapdh - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
hsp60  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology hsp60
Fig. 6 <t>HSP60</t> is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown
Hsp60, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/HSP+60+Antibody/pm38031139-172-29-30
Average 96 stars, based on 1 article reviews
hsp60 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
β tubulin  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology β tubulin
Fig. 6 <t>HSP60</t> is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown
β Tubulin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/GFP+Antibody/pm38031139-172-76-81
Average 96 stars, based on 1 article reviews
β tubulin - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
kr128 fastfire qpcr premix  (tiangen biotech co)
99
tiangen biotech co kr128 fastfire qpcr premix
Fig. 6 <t>HSP60</t> is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown
Kr128 Fastfire Qpcr Premix, supplied by tiangen biotech co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/FastFire+qPCR+PreMix/pm41886456-325-98-104
Average 99 stars, based on 1 article reviews
kr128 fastfire qpcr premix - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
histone h3  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc histone h3
Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone <t>H3</t> with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown
Histone H3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/Histone+H3+Antibody/pm38031139-172-60-62
Average 96 stars, based on 1 article reviews
histone h3 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
tri methyl histone h3 lys27  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc tri methyl histone h3 lys27
Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone <t>H3</t> with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown
Tri Methyl Histone H3 Lys27, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/checklist+original+data+file+s1+targetmol+anti+cancer+compound+library/Tri-Methyl-Histone+H3+(Lys27)+Rabbit+mAb/pm38031139-172-52-55
Average 95 stars, based on 1 article reviews
tri methyl histone h3 lys27 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


Fig. 3 TRIP12 modulates EZH2 target gene expression. A, B Relative mRNA expression of canonically-repressed and noncanonically-activated target genes of EZH2 upon siRNA-mediated knockdown of TRIP12 in YT (A) and NKYS (B). C, D Relative mRNA expression of canonically-repressed and noncanonically-activated target genes of EZH2 upon TRIP12 or empty vector transfection in YT (C) and NKYS (D). Results are mean ± SD. N = 3; N.S. not significant; *p < 0.05; **p < 0.01; ***p < 0.001

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 3 TRIP12 modulates EZH2 target gene expression. A, B Relative mRNA expression of canonically-repressed and noncanonically-activated target genes of EZH2 upon siRNA-mediated knockdown of TRIP12 in YT (A) and NKYS (B). C, D Relative mRNA expression of canonically-repressed and noncanonically-activated target genes of EZH2 upon TRIP12 or empty vector transfection in YT (C) and NKYS (D). Results are mean ± SD. N = 3; N.S. not significant; *p < 0.05; **p < 0.01; ***p < 0.001

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Targeted Gene Expression, Expressing, Knockdown, Plasmid Preparation, Transfection

Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Ubiquitin Proteomics, Phospho-proteomics, Transfection, Co-Immunoprecipitation Assay, Mutagenesis, Over Expression, Western Blot, Lysis

Fig. 6 HSP60 is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 6 HSP60 is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Co-Immunoprecipitation Assay, Western Blot, Knockdown, Over Expression

Fig. 7 Dexamethasone effectively targets the TRIP12-EZH2 cascade. (A, B) Immunoblots showing change of TRIP12 and EZH2 level upon dexamethasone treatment with indicated concentrations in NK92 (A) and YT (B). N = 3 individual experiments and representative images are shown. C Relative viability of ENKTL cells upon dexamethasone treatment for 48 h. Cell Counting Kit-8 assay was used to measure cell viability

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 7 Dexamethasone effectively targets the TRIP12-EZH2 cascade. (A, B) Immunoblots showing change of TRIP12 and EZH2 level upon dexamethasone treatment with indicated concentrations in NK92 (A) and YT (B). N = 3 individual experiments and representative images are shown. C Relative viability of ENKTL cells upon dexamethasone treatment for 48 h. Cell Counting Kit-8 assay was used to measure cell viability

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Western Blot, Cell Counting

Fig. 8 TRIP12-EZH2 axis regulates ENKTL cell migration. A–E The number of migrated NKTL cells to the lower compartment of transwell chamber with indicated transfections (A–D) or dexamethasone treatment (E, 48 h, 500 nM). The cells were subjected to transwell assay 16 h (A, B) or 24 h (C, D) after electroporation. N = 3; N.S. not significant; *p < 0.05; **p < 0.01; ***p < 0.001. F Schematic diagram illustrating the TRIP12-EZH2 signaling cascade

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 8 TRIP12-EZH2 axis regulates ENKTL cell migration. A–E The number of migrated NKTL cells to the lower compartment of transwell chamber with indicated transfections (A–D) or dexamethasone treatment (E, 48 h, 500 nM). The cells were subjected to transwell assay 16 h (A, B) or 24 h (C, D) after electroporation. N = 3; N.S. not significant; *p < 0.05; **p < 0.01; ***p < 0.001. F Schematic diagram illustrating the TRIP12-EZH2 signaling cascade

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Migration, Transfection, Transwell Assay, Electroporation

Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Ubiquitin Proteomics, Phospho-proteomics, Transfection, Co-Immunoprecipitation Assay, Mutagenesis, Over Expression, Western Blot, Lysis

Fig. 6 HSP60 is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 6 HSP60 is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Co-Immunoprecipitation Assay, Western Blot, Knockdown, Over Expression

E3 ligase TRIP12 correlates with EZH2 expression in extranodal natural killer/T-cell lymphoma (ENKTL). A Gene expression profiling (GEP) data showing EZH2 expression in ENKTL: 35 patient samples and 6 normal control tissues. B Co-IP showing interaction between EZH2 and TRIP12 or UHRF1 in YT (left) and NK92 cells (right). C EZH2 protein level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. N = 3 individual experiments and representative images are shown. ENKTL cells were harvested for immunoblots 48 h after knockdown with Neon transfection system. D EZH2 mRNA level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. ENKTL cells were harvested for RNA extraction 24 h after knock down. E EZH2 mRNA level change upon Flag-TRIP12 or empty vector transfection in YT (upper) and NKYS (lower) cells. The cells were harvested for RNA extraction 16 h after overexpression. Results are mean ± SD. N = 3; N.S. not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. F linear correlation between TRIP12 and EZH2 expression obtained from GEP data of 35 ENKTL patient samples (R = 0.76, p = 6.9e−07)

Journal: Clinical Epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: E3 ligase TRIP12 correlates with EZH2 expression in extranodal natural killer/T-cell lymphoma (ENKTL). A Gene expression profiling (GEP) data showing EZH2 expression in ENKTL: 35 patient samples and 6 normal control tissues. B Co-IP showing interaction between EZH2 and TRIP12 or UHRF1 in YT (left) and NK92 cells (right). C EZH2 protein level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. N = 3 individual experiments and representative images are shown. ENKTL cells were harvested for immunoblots 48 h after knockdown with Neon transfection system. D EZH2 mRNA level change upon TRIP12 knockdown using siRNA in YT (upper) and NKYS (lower) cells. ENKTL cells were harvested for RNA extraction 24 h after knock down. E EZH2 mRNA level change upon Flag-TRIP12 or empty vector transfection in YT (upper) and NKYS (lower) cells. The cells were harvested for RNA extraction 16 h after overexpression. Results are mean ± SD. N = 3; N.S. not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. F linear correlation between TRIP12 and EZH2 expression obtained from GEP data of 35 ENKTL patient samples (R = 0.76, p = 6.9e−07)

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkage-specific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Expressing, Gene Expression, Control, Co-Immunoprecipitation Assay, Knockdown, Western Blot, Transfection, RNA Extraction, Plasmid Preparation, Over Expression

Fig. 6 HSP60 is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 6 HSP60 is an upstream modulator of TRIP12-EZH2 signaling. A Co-IP showing interaction between HSP60 and EZH2 in YT (left) and NKYS (right) cells. B Co-IP showing interaction between HSP60 and SUZ12 in YT (left) and NKYS (right) cells. C Immunoblots indicating decrease of both TRIP12 and EZH2 with siRNA-mediated knockdown of HSP60 in NK92 cells. D Change of TRIP12 and EZH2 mRNA level with TRIP12 knockdown in YT (upper) and NKYS (lower) cells. E Change of interaction between HSP60 and EZH2 or its mutants with TRIP12 overexpression in HEK293T cells. N = 3 individual experiments and representative images are shown

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Co-Immunoprecipitation Assay, Western Blot, Knockdown, Over Expression

Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown

Journal: Clinical epigenetics

Article Title: EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.

doi: 10.1186/s13148-023-01606-6

Figure Lengend Snippet: Fig. 5 TRIP12 mediates EZH2 K634 ubiquitination and meanwhile enhances PRC2 stability and T487 phosphorylation. A Change of exogenously overexpressed EZH2 and endogenous p-EZH2 (T487) level with indicated transfections. B Co-IP showing change of interaction between TRIP12 and EZH2 mutant. C Schematic diagram indication: the conservation of EZH2 K634. (D) Co-IP showing change of interaction between EZH2 and PRC2 components or histone H3 with TRIP12 overexpression. E Co-IP showing change of interaction between EZH2 and CDK1 with or without TRIP12 overexpression. F Co-IP showing change of interaction between CDK1 and EZH2 mutant with TRIP12 overexpression. G Co-IP showing change of interaction between EZH2 or its mutants and SUZ12 with TRIP12 overexpression. All immunoblots or co-IPs were performed in HEK293T cells, and the cells were harvested for lysis 48 h after transfection. N = 3 individual experiments and representative images are shown

Article Snippet: Primary antibodies and drugs used in this study include: SUZ12 (Santa Cruz sc-271325, 1:1000), EED (Santa Cruz sc-518116, 1:1000), normal mouse IgG (Santa Cruz sc-2025), Flag (Beyotime AF519, 1:1000), HSP60 (Santa Cruz sc-13115, 1:1000), EZH2 (Cell Signaling Technology 3147 s, 1:1000), Anti-Ubiquitin (linkagespecific K63) (Abcam EPR8590-448, 1:1000), GAPDH (Santa Cruz sc-47724, 1:1000), Tri-Methyl-Histone H3 (Lys27) (Cell Signaling Technology C36B11, 1:1000), Histone H3 (Cell Signaling Technology D1H2, 1:2000), UHRF1 (Santa Cruz sc-373750, 1:1000), TRIP12 (proteintech 25303-1-AP, 1:1000), β-tubulin (Wanleibio WL01931, 1:750), GFP (Santa Cruz sc-9996, 1:1000), HA-probe (Santa Cruz sc-7392, 1:1000), HSP90 (Beyotime AH732, 1:1000), COX-IV (Wanleibio WL02203, 1:1000), CDK1 (Santa Cruz sc-54, 1:1000), EZH2 (Phospho-Thr487) (Signalway #12820, 1:1000), MG132 (Targetmol, 133407-82-6) and dexamethasone (Targetmol, T1076/50-02-2).

Techniques: Ubiquitin Proteomics, Phospho-proteomics, Transfection, Co-Immunoprecipitation Assay, Mutagenesis, Over Expression, Western Blot, Lysis